Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil P Shah

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
Blood|May 12, 2017
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysisCatherine C Smith, Amy Paguirigan, Grace R Jeschke, et al.
Leukemia & Lymphoma|October 25, 2019
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE studyNeil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, et al.
Haematologica|May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemiaKathryn E Flynn, Ehab Atallah, Li Lin, et al.
Nature|April 17, 2012
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaCatherine C Smith, Qi Wang, Chen-Shan Chin, et al.
Leukemia|July 31, 2024
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminibAriel Leyte-Vidal, RosaAnna DeFilippis, Ian R Outhwaite, et al.
Hematology (Amsterdam, Netherlands)|October 7, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phaseEhab Atallah, Michael S Broder, Onyee Chan, et al.
JAMA Network Open|December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid LeukemiaAaron N Winn, Ehab Atallah, Jorge Cortes, et al.
The New England Journal of Medicine|June 8, 2010
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaHagop Kantarjian, Neil P Shah, Andreas Hochhaus, et al.
The New England Journal of Medicine|November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemiasJorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Leukemia|January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
Blood|May 12, 2017
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysisCatherine C Smith, Amy Paguirigan, Grace R Jeschke, et al.
Leukemia & Lymphoma|October 25, 2019
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE studyNeil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, et al.
Haematologica|May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemiaKathryn E Flynn, Ehab Atallah, Li Lin, et al.
Nature|April 17, 2012
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaCatherine C Smith, Qi Wang, Chen-Shan Chin, et al.
Leukemia|July 31, 2024
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminibAriel Leyte-Vidal, RosaAnna DeFilippis, Ian R Outhwaite, et al.
Hematology (Amsterdam, Netherlands)|October 7, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phaseEhab Atallah, Michael S Broder, Onyee Chan, et al.
JAMA Network Open|December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid LeukemiaAaron N Winn, Ehab Atallah, Jorge Cortes, et al.
The New England Journal of Medicine|June 8, 2010
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaHagop Kantarjian, Neil P Shah, Andreas Hochhaus, et al.
The New England Journal of Medicine|November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemiasJorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Leukemia|January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Pageof 12